A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
A phase 3 trial of Cadonilimab, Sugemalimab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
Overview
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC is a phase 3 interventional study registered as NCT06617416 by Akeso, with 560 participants planned, started 2024-11-12 and due to reach its primary completion in 2026-10-28. Interventions recorded: Cadonilimab (AK104), Sugemalimab. Conditions listed: NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Cadonilimab, Akeso.
- TrialA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Shares Cadonilimab, Akeso.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Cadonilimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
Shares Cadonilimab, Akeso.
- TrialA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat
Shares Cadonilimab, Akeso.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Cadonilimab, Akeso.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Akeso, Small-cell lung cancer, Non-small-cell lung cancer.